Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

Neurocrine Biosciences, Inc. will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer ...

RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

Neurocrine Biosciences, Inc. today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound ...

- Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As part of Xenon's ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy, NBI-921355, a Nav1.2 and Nav1.6 sodium channel inhibitor in development for the potential ...

SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. (PRNewsfoto ...

Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information ...